Thyroid-Stimulating Hormone–Receptor Antibody and Thyroid Hormone Concentrations in Smokers vs Nonsmokers With Graves Disease Treated With Carbimazole
Authors:
- Moffat J NyirendaMNMoffat J Nyirenda
- Peter N TaylorPTPeter N Taylor
- Mary StoddartMSMary Stoddart
- Geoffrey J BeckettGBGeoffrey J Beckett
- Anthony D ToftATAnthony D Toft
- 14 January 2009
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA
- Vol. 301 (2) , 162-164
Abstract
Letter from JAMA — Thyroid-Stimulating Hormone–Receptor Antibody and Thyroid Hormone Concentrations in Smokers vs Nonsmokers With Graves Disease Treated With CarbimazoleKeywords
This publication has 5 references indexed in Scilit:
- Effect of pregnancy on a measure of FMO3 activityBritish Journal of Clinical Pharmacology, 2005
- Remission of Graves' Hyperthyroidism Predicted by Smooth Decreases of Thyroid-Stimulating Antibody and Thyrotropin-Binding Inhibitor Immunoglobulin During Antithyroid Drug TreatmentThyroid®, 2000
- Analysis of serial measurements in medical research.BMJ, 1990
- Carbimazole and the Autoimmune Response in Graves' DiseaseNew England Journal of Medicine, 1980
- The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients.1980